Journal of Psychopharmacology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to register today!

Click here to register today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (47)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baldwin, D. S.
Right arrow Articles by Wittchen, H. -U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baldwin, D. S.
Right arrow Articles by Wittchen, H. -U.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Psychopharmacology, Vol. 19, No. 6, 567-596 (2005)
DOI: 10.1177/0269881105059253
© 2005 British Association for Psychopharmacology

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

David S. Baldwin

Division of Clinical Neurosciences, University of Southampton, Southampton, UK, dsb1{at}soton.ac.uk

Ian M. Anderson

Department of Psychiatry, University of Manchester, Manchester, UK

David J. Nutt

University of Bristol, Bristol, Psychopharmacology Unit, Bristol, UK

Borwin Bandelow

Department of Psychiatry and Psychotherapy, University of Göttingen, Göttingen, Germany

A. Bond

Institute of Psychiatry, King’s College, London, UK

Jonathan R. T. Davidson

Department of Psychiatry & Behavioral Science, Duke University Medical Center, Durham, USA

J. A. den Boer

School of Behavioral and Cognitive Neurosciences, University Medical Center Groningen, Groningen, the Netherlands

Naomi A. Fineberg

Department of Psychiatry, University of Hertfordshire, Welwyn Garden City, UK

Martin Knapp

Institute of Psychiatry, King’s College, London, UK

J. Scott

Institute of Psychiatry, King’s College, London, UK

H. -U. Wittchen

Technical University of Dresden and Max Planck Institute of Psychiatry, Munich, Germany

These British Association for Psychopharmacology guidelines cover the range and aims of treatment for anxiety disorders. They are based explicitly on the available evidence and are presented as recommendations to aid clinical decision making in primary and secondary medical care. They may also serve as a source of information for patients and their carers. The recommendations are presented together with a more detailed review of the available evidence. A consensus meeting involving experts in anxiety disorders reviewed the main subject areas and considered the strength of evidence and its clinical implications. The guidelines were constructed after extensive feedback from participants and interested parties. The strength of supporting evidence for recommendations was rated. The guidelines cover the diagnosis of anxiety disorders and key steps in clinical management, including acute treatment, relapse prevention and approaches for patients who do not respond to first-line treatments.

Key Words: anticonvulsants • antidepressants • antipsychotics • anxiety disorders • anxiolytics • benzodiazepines • cognitive behaviour therapy • evidence-based guidelines • generalized anxiety disorder • obsessive-compulsive disorder • panic disorder • post-traumatic stress disorder • simple phobia • social phobia • SSRI • treatment • venlafaxine


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J PsychopharmacolHome page
D. J. Nutt and M. Sharpe
Uncritical positive regard? Issues in the efficacy and safety of psychotherapy
J Psychopharmacol, January 1, 2008; 22(1): 3 - 6.
[PDF]


Home page
J PsychopharmacolHome page
C. Haw and J. Stubbs
Benzodiazepines a necessary evil? A survey of prescribing at a specialist UK psychiatric hospital
J Psychopharmacol, August 1, 2007; 21(6): 645 - 649.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
R. J. Rodgers
More haste, considerably less speed
J Psychopharmacol, March 1, 2007; 21(2): 141 - 143.
[PDF]


Home page
Psychiatr. Bull.Home page
L. M. Drummond, A. Pillay, P. Kolb, and S. Rani
Specialised in-patient treatment for severe, chronic, resistant obsessive-compulsive disorder
Psychiatr. Bull., February 1, 2007; 31(2): 49 - 52.
[Abstract] [Full Text] [PDF]


Home page
FocusHome page
L. M. Koran M.D.
Obsessive-Compulsive Disorder: An Update for the Clinician
Focus, January 1, 2007; 5(3): 299 - 313.
[Full Text] [PDF]


Home page
J PsychopharmacolHome page
D. J. Nutt, K. Fone, P. Asherson, D. Bramble, P. Hill, K. Matthews, K. A. Morris, P. Santosh, E. Sonuga-Barke, E. Taylor, et al.
Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology
J Psychopharmacol, January 1, 2007; 21(1): 10 - 41.
[Abstract] [PDF]